Fanous Marina, Gold Sarah, Hirsch Stefan, Ogorka Joerg, Imanidis Georgios
Novartis Pharma AG, Basel, Switzerland; Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
Novartis Pharma AG, Basel, Switzerland.
Eur J Pharm Sci. 2020 Dec 1;155:105558. doi: 10.1016/j.ejps.2020.105558. Epub 2020 Sep 16.
Pharmaceutical 3D-printing represents a potentially new dosing and manufacturing approach for the pharmaceutical industry, with unique opportunities for personalization of dosage strengths. Fused deposition modelling (FDM) is a 3D-printing technique, which presents advantages for decentralized on-site manufacturing in hospitals and pharmacies. This study introduces industrially relevant development of formulations for filaments with the required mechanical properties to be 3D-printable and providing immediate release (IR) dosage forms using safe materials approved also for pediatric use. Hydroxypropyl-cellulose (HPC) SSL was chosen as hydrophilic polymer and caffeine with a load of 5-20% as thermally stable model drug. Poly-(vinyl pyrrolidone-vinyl acetate) copolymer (Kollidon VA64) and poly-(vinyl alcohol-polyethylene glycol) graft copolymer (Kollicoat IR) were additional water-soluble polymers tested in combination with HPC and xylitol and polyethylene glycol (PEG) 4000 were evaluated as hydrophilic plasticizers and PEG4000 and maltodextrin as pore formers. Formulations were hot-melt extruded using a scalable twin-screw extruder and 3D-printed into honeycomb geometry solid dosage forms with high (100%) and low (80%) infill density. Rapid or very rapid release was achieved via formulation selection and tablet design parameters. PEG4000 in combination with Kollidon VA64 demonstrated superior processability and significantly accelerated release properties of the matrix independently of infill density. Lowering caffeine content improved hot-melt extrusion processability for each formulation but prolonged dissolution. The use of Kollicoat IR resulted in superior mechanical properties of the manufactured filaments, with easy handling and successful 3D-printing for drug load of 5 to 20%. For most formulations, lowering infill density of 3D-printed tablets yielded faster drug dissolution in agreement with the literature. However, the extent of the infill density effect varied depending on formulation. Caffeine was present in stable crystalline state in 3D-printed tablets. Printing temperature appeared to be critical for drug dissolution in vitro. This wide-ranging excipient investigation epitomizes the beginning of a toolbox approach targeting FDM processability in combination with immediate release characteristics of personalized dosage forms.
药物3D打印为制药行业提供了一种潜在的新型给药和制造方法,在剂型强度个性化方面具有独特机遇。熔融沉积建模(FDM)是一种3D打印技术,在医院和药房的分散式现场制造中具有优势。本研究介绍了具有所需机械性能以便可进行3D打印的丝状制剂的工业相关开发,并使用也被批准用于儿科的安全材料提供速释(IR)剂型。选择羟丙基纤维素(HPC)SSL作为亲水性聚合物,选择负载量为5 - 20%的咖啡因作为热稳定模型药物。聚(乙烯基吡咯烷酮 - 醋酸乙烯酯)共聚物(聚乙烯聚维酮)和聚(乙烯醇 - 聚乙二醇)接枝共聚物(尤特奇IR)是与HPC联合测试的其他水溶性聚合物,木糖醇和聚乙二醇(PEG)4000被评估为亲水性增塑剂,PEG4000和麦芽糊精被评估为成孔剂。使用可扩展的双螺杆挤出机对制剂进行热熔挤出,并3D打印成具有高(100%)和低(80%)填充密度的蜂窝状几何形状固体剂型。通过制剂选择和片剂设计参数实现了快速或极快速释放。PEG4000与聚乙烯聚维酮联合使用表现出优异的加工性能,并且显著加速了基质的释放性能,与填充密度无关。降低咖啡因含量改善了每种制剂的热熔挤出加工性能,但延长了溶出时间。使用尤特奇IR导致所制造丝状材料具有优异的机械性能,对于5%至20%的药物负载量易于处理且能成功进行3D打印。对于大多数制剂,降低3D打印片剂的填充密度会使药物溶出更快,这与文献一致。然而,填充密度效应的程度因制剂而异。咖啡因在3D打印片剂中以稳定的结晶状态存在。打印温度似乎对体外药物溶出至关重要。这种广泛的辅料研究代表了一种工具箱方法的开端,该方法针对FDM加工性能并结合个性化剂型的速释特性。